Huaigeng Xu

Huaigeng Xu

Auto-generated profile, based on publicly available information

Huaigeng Xu

Department of Clinical Application, CiRA, Kyoto University, Kyoto, Japan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Cell Stem Cell
Verified
Journal Article
Closed access
HXHuaigeng Xu
Huaigeng Xu
BWBo Wang
Bo Wang
MOMiyuki Ono
Miyuki Ono
AKAkihiro Kagita
Akihiro Kagita
KFKaho Fujii
Kaho Fujii
AHAkitsu Hotta
Akitsu Hotta

13 March 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
PGPeter Gee
Peter Gee
MLMandy S. Y. Lung
Mandy S. Y. Lung
YOYuya Okuzaki
Yuya Okuzaki
NSNoriko Sasakawa
Noriko Sasakawa
TITakahiro Iguchi
Takahiro Iguchi
AHAkitsu Hotta
Akitsu Hotta
Prolonged expression of the CRISPR-Cas9 nuclease and gRNA from viral vectors may cause off-target mutagenesis and immunogenicity. Thus, a transient delivery system is needed for therapeutic genome editing applications. Here, we develop an extracellular nanovesicle-based ribonucleoprotein delivery system named NanoMEDIC by utilizing two distinct homing mechanisms. Chemical induced dimerization recruits Cas9 protein into extracellular nanovesicles, and then a viral RNA packaging signal and two self-cleaving riboswitches tether and release sgRNA into nanovesicles. We demonstrate efficient genome editing in various hard-to-transfect cell types, including human induced pluripotent stem (iPS) cells, neurons, and myoblasts. NanoMEDIC also achieves over 90% exon skipping efficiencies in skeletal muscle cells derived from Duchenne muscular dystrophy (DMD) patient iPS cells. Finally, single intramuscular injection of NanoMEDIC induces permanent genomic exon skipping in a luciferase reporter mouse and in mdx mice, indicating its utility for in vivo genome editing therapy of DMD and beyond.

6 December 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
HMHiroyuki Morisaka
Hiroyuki Morisaka
KYKazuto Yoshimi
Kazuto Yoshimi
YOYuya Okuzaki
Yuya Okuzaki
PGPeter Gee
Peter Gee
YKYayoi Kunihiro
Yayoi Kunihiro
TMTomoji Mashimo
Tomoji Mashimo
Although single-component Class 2 CRISPR systems, such as type II Cas9 or type V Cas12a (Cpf1), are widely used for genome editing in eukaryotic cells, the application of multi-component Class 1 CRISPR has been less developed. Here we demonstrate that type I-E CRISPR mediates distinct DNA cleavage activity in human cells. Notably, Cas3, which possesses helicase and nuclease activity, predominantly triggered several thousand base pair deletions upstream of the 5′-ARG protospacer adjacent motif (PAM), without prominent off-target activity. This Cas3-mediated directional and broad DNA degradation can be used to introduce functional gene knockouts and knock-ins. As an example of potential therapeutic applications, we show Cas3-mediated exon-skipping of the Duchenne muscular dystrophy (DMD) gene in patient-induced pluripotent stem cells (iPSCs). These findings broaden our understanding of the Class 1 CRISPR system, which may serve as a unique genome editing tool in eukaryotic cells distinct from the Class 2 CRISPR system.

17 May 2021 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
BWBo Wang
Bo Wang
SIShoichi Iriguchi
Shoichi Iriguchi
MWMasazumi Waseda
Masazumi Waseda
NUNorihiro Ueda
Norihiro Ueda
TUTatsuki Ueda
Tatsuki Ueda
SKShin Kaneko
Shin Kaneko

1 January 2020 in Stem Cell Reports
Verified
Journal Article
Open access
DSDaisuke Suzuki
Daisuke Suzuki
CFCharlotte Flahou
Charlotte Flahou
NYNorihide Yoshikawa
Norihide Yoshikawa
ISIeva Stirblyte
Ieva Stirblyte
YHYoshikazu Hayashi
Yoshikazu Hayashi
NSNaoshi Sugimoto
Naoshi Sugimoto
The ex vivo production of platelets depleted of human leukocyte antigen class I (HLA-I) could serve as a universal measure to overcome platelet transfusion refractoriness caused by HLA-I incompatibility. Here, we developed human induced pluripotent cell-derived HLA-I-deficient platelets (HLA-KO iPLATs) in a clinically applicable imMKCL system by genetic manipulation and assessed their immunogenic properties including natural killer (NK) cells, which reject HLA-I downregulated cells. HLA-KO iPLATs were deficient for all HLA-I but did not elicit a cytotoxic response by NK cells in vitro and showed circulation equal to wild-type iPLATs upon transfusion in our newly established Hu-NK-MSTRG mice reconstituted with human NK cells. Additionally, HLA-KO iPLATs successfully circulated in an alloimmune platelet transfusion refractoriness model of Hu-NK-MISTRG mice. Mechanistically, the lack of NK cell-activating ligands on platelets may be responsible for evading the NK cell response. This study revealed the unique non-immunogenic property of platelets and provides a proof of concept for the clinical application of HLA-KO iPLATs.

1 November 2018 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
YZYulia Zhitnyuk
Yulia Zhitnyuk
PGPeter Gee
Peter Gee
MLMandy S.Y. Lung
Mandy S.Y. Lung
NSNoriko Sasakawa
Noriko Sasakawa
HXHuaigeng Xu
Huaigeng Xu
AHAkitsu Hotta
Akitsu Hotta